The Cooper (The Cooper) Risk Assessment

View and export this data going back to 1983. Start your Free Trial

What is The Cooper Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of The Cooper is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of The Cooper's Risk Assessment

For the Medical Instruments & Supplies subindustry, The Cooper's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

The Cooper's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's Risk Assessment distribution charts can be found below:

* The bar in red indicates where The Cooper's Risk Assessment falls into.

The Cooper (NAS:COO) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

The Cooper Risk Assessment Related Terms

Thank you for viewing the detailed overview of The Cooper's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

The Cooper (The Cooper) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » The Cooper Companies Inc (NAS:COO) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

COO:Mexico CP6:Germany C1OO34:Brazil

Address

6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, USA, 94583

Website

https://www.coopercos.com

The Cooper Companies is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business and is composed of a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and clariti, Cooper controls roughly a quarter of the U.S. contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the U.S., and controls 17% of the U.S. IUD market.

Executives

Gary S Petersmeyer	director	3400 CENTRAL AVENUE, SANTA CLARA CA 95051
Robert S Weiss	director, officer: EVP and CFO	6140 STANERIDGE MALL RES #590, PLEASSANTON CA 94503
Agostino Ricupati	officer: Sr. VP, Finance & Tax	C/O THE COOPER COMPANIES, INC., 6140 STONERIDGE MALL ROAD, SUITE 590, PLEASANTON CA 94588
Warner Gerard H Iii	officer: President, CooperVision, Inc.	C/O COOPER COMPANIES INC., 6101 BOLLINGER CANYON ROAD, SUITE 500, SAN RAMON CA 94583
Jody S Lindell	director	2536 FILLMORE ST., SAN FRANCISCO CA 94115
Cynthia L Lucchese	director	7966 N. ILLINOIS STREET, INDIANAPOLIS IN 46260
Nicholas Khadder	officer: VP, General Counsel & Corp Sec	2836 JOHNSON AVENUE, ALAMEDA CA 94501
Daniel G Mcbride	officer: VP and Senior Counsel	5 EL CORTE, ORINDA CA 94563
Brian G Andrews	officer: Treasurer	4300A 17TH STREET, SAN FRANCISCO CA 94114
Maria Rivas	director	C/O MEDIDATA SOLUTIONS, INC., 350 HUDSON STREET, 9TH FLOOR, NEW YORK NY 10014
White Albert G Iii	officer: VP & Treasurer	6790, SPRINGDALE COURT, VICTOR NY 14564
Teresa S Madden	director	414 NICOLLET MALL, MINNEAPOLIS MN 55401
Robert D Auerbach	officer: President, CSI	C/O THE COOPER COMPANIES, INC., SUITE 590, PLEASANTON CA 94588
Holly R Sheffield	officer: EVP, CSO	C/O THE COOPER COMPANIES, INC., 6140 STONERIDGE MALL ROAD, SUITE 590, PLEASANTON CA 94588
Mark J Drury	officer: VP, General Counsel & Sec.	C/O COOPERCOMPANIES, 6101 BOLLINGER CANYON ROAD, SUITE 500, SAN RAMON CA 94583